 LEXINGTON, Mass., June 4, 2021 PRNewswire -- Curis, Inc. NASDAQ: CRIS, a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will host a virtual KOL event to discuss progress to date for CA-4948, a first-in-class IRAK4 kinase inhibitor, including updated data presented at the European Hematology Association 2021 Virtual Congress from the Phase 12 study of CA-4948 in patients with AML or high-risk MDS. 